Penny Roger$
12 years ago
~ $EROX ~Multi chart fix and On the house shots of DD!! Version 3.2.3
~ Barchart: http://barchart.com/quotes/stocks/EROX?
~ OTC Markets: http://www.otcmarkets.com/stock/EROX/company-info
~ Google Finance: http://www.google.com/finance?q=EROX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=EROX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=EROX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=EROX
Finviz: http://finviz.com/quote.ashx?t=EROX
~ BusyStock: http://busystock.com/i.php?s=EROX&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=EROX&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=EROX
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=EROX
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=EROX
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=6768&srchyr=2011&SearchStr=EROX
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=EROX
~ MarketWatch: http://www.marketwatch.com/investing/stock/EROX/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=EROX
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=EROX
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=EROX&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=EROX&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=EROX&size=l&frequency=60&color=g
DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=EROX
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=EROX
Check those searches for recent EROX mentions. If EROX is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a cEROXnt list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=8&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=2&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=25&y=5
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=8&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=2&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=36&y=14
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=8&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=2&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=28&y=15
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=6&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=39&y=17
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=6&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=35&y=12
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=6&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=23&y=19
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=18&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=8&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=38&y=6
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=18&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=8&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=30&y=11
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=&symb=EROX&time=18&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=8&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=35&y=14
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=3&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=7&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=39&y=14
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=3&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=7&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=20&y=16
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=3&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=7&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=46&y=6
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=6&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=42&y=20
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=6&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=36&y=11
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=6&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=46&y=11
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=9&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=31&y=14
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=9&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=23&y=15
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=EROX&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=9&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=22&y=15
---------------------
---------------------
* If a symbol changes or adds a D, etc. Message me for an updated version.
Twitter: @MACDgyver ---> EROX <---
SumTingWong
14 years ago
Human Pheromone Sciences, ACI, Inc. and Marilyn Miglin Announce the Introduction of Their Initial Fragrance on Home Shopping Network
Published: October 29, 2009
SAN JOSE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company"), ACI, Inc. and Marilyn Miglin LLC announced the initial product generated by their collaborative efforts to create a fragrance collection, Marilyn Miglin's Sixth Sense, will be introduced on Home Shopping Network (HSN)., commencing Sunday, November 1, 2009.
The parties were introduced through New York City based BIG (Brand Intelligence Group, Inc.) who handles the branding and licensing of several fashion, beauty and lifestyle brands. "We are delighted to join together two innovative and dynamic companies to collaborate on a new venture," said Deborah Moses, co--founder of BIG. "Marilyn Miglin is synonymous with fragrance and understanding the tastes of today's consumer. So it was only natural for her to look toward technology to enhance her 30(th) fragrance introduction into the market place with Marilyn Miglin's Sixth Sense."
This is a groundbreaking new essence, an intriguing marriage of sensuality and empowerment that delivers a new sensory experience. The wearer is more confident and radiant with her presence heightened to all of those around her.
The fragrance is a unique addition to Marilyn Miglin's highly successful portfolio of fragrances with a sensory-dynamic quality that enhances allurement and self-assurance offering a truly new experience in fragrance. "It's a flawless collaboration of Marilyn, her perfumers and the HPS chemists to create a mysterious, ultra feminine and elegant scent," said Joanne Benjamin, President of ACI, a vendor to HSN for over 20 years. "Marilyn Miglin's Sixth Sense will provide a warm, long lasting, sensual background that awakens the provocateur in the wearer."
Human Pheromone Sciences, Inc. is a technology-based company, whose products include prestige and mass-priced fragrances, toiletries and environmental products. The Company has Licensing and Distribution Agreements with Johnson & Johnson, Inc., Schwarkopf and Henkel, Dial Corporation and an exclusive agreement with Pheromone International Co., Ltd. in Taiwan. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain and have worldwide patents pending on another compound originally found in Coral Reefs. Further information is available online at www.erox.com.
The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2008, and Form 10-Q for the quarter and six months ended June 30, 2009, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.
SOURCE Human Pheromone Sciences, Inc.
More Press Releases
Human Pheromone Sciences Announces Third Quarter Results
November 13, 2009 - PR Newswire
RELATED ADSwhat are related ads?
di4
15 years ago
Human Pheromone Sciences Announces First Quarter Results
May 14, 2009 4:10:00 PM
Email Story Discuss on ZenoBank
View Additional ProfilesCurrent Period Results Impacted by Downturn in Worldwide Beauty Markets
SAN JOSE, Calif., May 14 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or the "Company") today announced results for the first quarter ended March 31, 2009. Net revenues of $165,000 represented a 38% decrease from the revenues of $266,000 in the prior year period, and resulted in a net loss of $181,000 ($0.04 per share) as compared with net loss of $63,000 ($0.02 per share) for the same period of 2008. At March 31, 2009, the Company reflected cash balances of $664,000 compared with $907,000 in cash at December 31, 2008, a $243,000 reduction in the quarter. There was no bank indebtedness at either period.
According to a Company spokesperson, "the revenue and cash declines were in line with the Company's internal forecasts, reflecting the extremely difficult overall adverse economic climate and the significant downturn in the worldwide Fragrance and Beauty Markets. We had anticipated the reduction of revenues on sales to our once largest fragrance and beauty-based company, and, as such, embarked upon a program to expand other potential markets for the use of our patented technology in other consumer product arenas. Some of the shortfall in the basic beauty area was offset by supply and royalty revenues received under our licensing agreement with Schwarzkopf & Henkel in the worldwide hair care and personal product markets. Pheromone purchases by our two primary licensees, increased by 79%, in anticipation of a new product launch in May 2009 by one of these companies. While the selling price of the pheromones is quite low compared to that of prior licensees, our newer agreements provide for royalties on licensee sales of products containing our patented technology. As such, we would anticipate an increase in royalty income in subsequent periods this year."
"Generating additional revenues under new licensing agreements will not only grow our business, but will reduce the effect of erratic purchasing patterns by one major licensee. In addition, while the Company is focusing on reducing expenditures, we continue to invest in maintaining our current patents and seeking such protection for our newest technology on a worldwide basis," the spokesperson indicated.
Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at www.erox.com.
The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2008, and Form 10-Q for the quarter ended March 31, 2009, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.
Tables follow
HUMAN PHEROMONE SCIENCES, INC.
Condensed Balance Sheets
(Dollars in thousands)
March 31, December 31,
2009 2008
---- ----
(Unaudited)
Assets
Cash and cash equivalents $664 $907
Accounts receivable 61 52
Inventories, net 51 39
Other current assets 34 58
Property and equipment, net 2 2
----------- -----------
Total $812 $1,058
=========== ===========
Liabilities and shareholders' deficit
Accounts payable $54 $19
Other current liabilities 103 131
Deferred income - current 270 297
Deferred income - non-current 265 324
Common stock 21,056 21,043
Accumulated deficit (20,936) (20,756)
----------- -----------
Total $812 $1,058
=========== ===========
HUMAN PHEROMONE SCIENCES, INC.
Condensed Statements of Operations
(Unaudited)
(Dollars in thousands, except per-share data)
Three months ended March 31,
2009 2008
------ ------
Net revenues $165 $266
Cost of goods sold 65 81
Research and development 25 14
Selling, general and administrative 257 244
------ ------
Income (loss) from operations (182) (73)
Other income 1 11
Provision for income taxes - 1
------ ------
Net income (loss) $(181) $(63)
====== ======
Income (loss) per share, basic $(0.04) $(0.02)
====== ======
Income (loss) per share, fully diluted $(0.04) $(0.02)
====== ======
Weighted average common shares
Outstanding - Basic 4,152 4,152
====== ======
Weighted average common shares
Outstanding - Fully diluted 4,152 4,152
====== ======
Net income (loss) per share is based on the weighted average number of
common shares and common equivalents outstanding during each period.
Certain common stock equivalents are excluded when their effect would be
anti-dilutive.
SOURCE Human Pheromone Sciences, Inc.
----------------------------------------------
William P. Horgan
Chairman
CEO of Human Pheromone Sciences
Inc.
+1-408-938-3030
SumTingWong
16 years ago
October 27, 2008 - 2:02 PM EDT
EROX 0.30 0.07
Today 5d 1m 3m 1y 5y 10y
Human Pheromone Sciences, Inc. - Shareholder Update
SAN JOSE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- HPSI (OTC Bulletin Board: EROX) releases letter to its shareholders
Dear Shareholders,
In light of events that have shaken the investment community around the
world over the past several weeks, I want to take this opportunity to
update you as to what is happening in your Company at the present time.
Excluding technology advancements, an update of which will be provided
very shortly in another release, the objectives and strategies for the
Company for this year and 2009 are as follows:
-- The Company is continuing to work closely with our current licensees as
they undertake programs to introduce consumer products containing our
patented compounds.
During this year we have continued to be closely involved with the J&J
Personal Products Group as they continue product development efforts
under our License Agreement. This project is ongoing and viable.
In mid 2007, we entered into an agreement with Schwarzkopf and Henkel,
for the inclusion of our patented technology in several of their got2b
brand products sold in the United States. During this year, the
Agreement has been expanded geographically to include Henkel's European
businesses and an additional product line has been included in the
Agreement.
We continue, this year, to work with other U.S. and international
companies including Avon Products, who continue to utilize our
pheromone compounds. In addition, we continue to look
internationally, and continue to enter into agreements with companies
doing business in Mexico and Japan.
In addition, we are in discussions with several other companies in the
United States and overseas, in efforts to open new markets for our
current technology with local companies, with their own infrastructures
here in this country and in foreign markets.
Not only has our Company benefited financially from our agreements with
these world-class companies, our association with them has confirmed
the viability of our technology, an imperative for a small
technology-based business to generate interest of others in the longer
term.
-- While our historical business model has been validated by these
relationships, we are still dependent upon the internal timetable of
these licensees for the generation of revenues for our Company.
However, there are other viable and fast growing channels in which
consumer products are sold, including electronic media, and
direct-to-consumer companies, that may provide a more consistent flow
of revenues to our Company. During this year, your management has been
working to introduce our technology to several companies who are in
leaders in these fields. We hope to be able to provide more specifics
about these efforts shortly.
-- Technology - our heritage, our future; another focus of our Company.
During 2008, we have spent significant amounts of time, but not a lot
of money, in the development of new compounds. You will be hearing
more about the positive results of these efforts in the next two weeks.
-- Merger and Acquisition Opportunities. We feel strongly that our
current technology and new research and development initiatives can
continue to attract world-class partners. We have also undertaken a
program to seek mergers and/or other types of partnerships that can
enhance shareholder value - our ultimate goal.
Unlike many companies whose share price has dropped radically this year,
who have no historic operations, an un-tested business plan and tens of
millions of shares outstanding, our Company has existing relationships and
agreements with worldwide leaders in the consumer products industry, is in
discussions with other international companies for the use of our
technology, looking to expand our relationships to provide a more
consistent stream of revenues, and has a pipeline of additional compounds
that can offer patented differentiation. And, importantly, our cash
assets exceed our current market valuation, and we have no
interest-bearing debt.
Thank you for interest and support. Please do not hesitate to contact me
directly if you have any questions.
Sincerely,
William P. Horgan
Chairman and CEO
408-938-3030
SOURCE Human Pheromone Sciences, Inc.
righty
16 years ago
This pr for the patent filing seems to indicate the research has come to a head on this product, if nothing else a little sampling of the product would serve as a fun experiment lol
Let's roll out the DD here, this might be an interesting development.
October 17, 2007 - 8:02 AM EDT
Human Pheromone Sciences Files U.S. Provisional Patent for Naturally-Occurring Compound After Years of Studies and Research
SAN JOSE, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ('HPS' or 'the Company') announced today that it filed a Provisional Patent Application with the U.S. Patent and Trademark Office for the use of a novel compound found in nature which has significant positive impacts on both men and women.
'Our scientists have been working for more than eight years, from the initial discovery of this naturally-occurring compound that has its roots in the sea, reproducing it in the laboratory, conducting scientific trials with male and female volunteers and developing a manufacturing process for commercial quantities. Physiological and psychological testing has shown statistically significant increases in a host of positive emotions and feelings in both men and women, including increased feelings of wellness, warmth, sensuality and personal well-being.
'This is a very exciting discovery by our scientists, and the results of human testing exceeded our initial expectations. The patent application is broad-based and covers the use of this compound in a host of potential consumer, personal care, household and environmental products,' a Company spokesperson indicated. The spokesperson also disclosed that it is actively working on other novel compounds that have shown positive results in preliminary research studies.
Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of-concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company has also entered into agreements with leading consumer products companies, such as Avon Products, Johnson & Johnson and Schwarzkopf & Henkel to incorporate the Company's initial technology in their consumer products. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at http://www.erox.com.
The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2006, and Form 10-Q for the six months ended June 30, 2007 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.
SOURCE Human Pheromone Sciences, Inc.
Source: PR Newswire (October 17, 2007 - 8:02 AM EDT)
News by QuoteMedia
www.quotemedia.com
righty
16 years ago
December 10, 2007 - 2:32 PM EST
Human Pheromone Sciences Announces Stock Repurchase Program
SAN JOSE, Calif., Dec. 10 /PRNewswire/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ('HPS' or 'the Company') today announced today that its Board of Directors has authorized the repurchase of up to 400,000 shares of common stock, representing approximately 10% of the current shares outstanding, from time to time in the open market and private transactions. The plan sets no time limit for any repurchases. A spokesperson indicated that 'the Company is committed to a long-term share repurchase program as part of an overall capital allocation that supports growth and also returns value to shareholders.'
Human Pheromone Sciences, Inc. is a technology-based company, whose proof- of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at http://www.erox.com.
The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2006, and Form 10-QSB for the quarters ended March 31, 2007, June 30, 2007 and September 30, 2007, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.
SOURCE Human Pheromone Sciences, Inc.
Source: PR Newswire (December 10, 2007 - 2:32 PM EST)
News by QuoteMedia
www.quotemedia.com
righty
16 years ago
November 13, 2007 - 12:01 PM EST
Human Pheromone Sciences Announces Third Quarter Results
Initiatives to Expand Business Potential Achieve Milestones in Quarter
SAN JOSE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ('HPS' or 'the Company') today announced results for the third quarter ended September 30, 2007. Net revenues of $239,000 compared with $365,000 in the prior year period resulted in a net loss of $93,000 ($.02 per share) as compared with a net income of $49,000 ($.01 per share) for the same period of 2006. For the nine month period in 2007 net revenues grew by 11% to $902,000 from $815,000, and the net loss for the first nine months of 2007 was $54,000 ($.01 per share), a $123,000 (70%) improvement from the 2006 net loss of $177,000 ($.04 per share) incurred in the first nine months of the prior year. At September 30, 2007, basic liquidity (cash plus accounts receivable, less accounts payable and accrued expenses) was $1,455,000 as compared with $1,836,000 at December 31, 2006, reflecting net spending of $381,000 for the nine months of the current year.
'In the third and fourth quarters of 2006, we had sizable orders from our largest purchaser of pheromones and we do not expect comparable orders in the current year. These cyclical purchases are unpredictable and, as such, we developed a set of strategic imperatives to grow our licensing revenues (which were up by more than 175% in the current year's quarter), formulate a program to maximize revenues from our proprietary Natural Attractions(R) brand and complete human testing on additional novel compounds that can contribute to the expansion of our business through the scientific validation of additional technologies that will enhance the value of our Company,' a spokesman indicated. During the third quarter of the current year, the Company received its first royalty payment from a licensing pact, signed earlier in the year with a major International corporation for our original compounds, signed an agreement to update, repackage and reposition the Company's proprietary Natural Attraction(R) line of products and filed a patent application for an exciting new compound that has shown significant potential in human studies. 'While we are not pleased by the financial results for the current quarter as compared with the prior year three month period, we believe that focus on these three strategic imperatives will lessen our dependence on the purchasing pattern of one large customer, and ensure balanced growth in revenue and an expanded technology and customer base, without major capital investment,' the spokesman further noted.
Human Pheromone Sciences, Inc. is a technology-based company, whose proof- of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at http://www.erox.com.
The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2006, and Form 10-QSB for the quarters ended March 31, 2007, June 30, 2007 and September 30, 2007, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward- looking statements.
HUMAN PHEROMONE SCIENCES, INC.
Condensed Balance Sheets
(Dollars in thousands)
September 30, December 31,
2007 2006
(Unaudited)
Assets
Cash and cash equivalents $1,550 $1,941
Accounts receivable 60 39
Inventories, net 76 75
Other current assets 35 18
Property and equipment, net 1 2
Total assets $1,722 $2,075
Liabilities and shareholders' equity
Accounts payable $48 $30
Other current liabilities 107 114
Deferred revenue - current 508 846
Deferred revenue - non-current 681 721
Common stock 20,933 20,865
Accumulated deficit (20,555) (20,501)
Total liabilities and shareholders' equity $1,722 $2,075
HUMAN PHEROMONE SCIENCES, INC.
Condensed Statements of Operations
(Unaudited)
(Dollars in thousands, except per-share data)
Three months Nine months
ended September 30, ended September 30,
2007 2006 2007 2006
Net revenues $239 $365 $902 $815
Cost of goods sold 94 68 277 179
Research and development 10 29 38 88
Selling, general and
administrative 240 227 686 734
Income (loss) from
operations (105) 41 (99) (186)
Other income 16 8 50 9
Provision for income taxes 4 - 5 -
Net income (loss) $(93) $49 $(54) $(177)
Income (loss) per
share, basic: $(0.02) $0.01 $(0.01) $(0.04)
Income (loss) per
share, fully diluted: $(0.02) $0.01 $(0.01) $(0.04)
Weighted average
common shares
outstanding-
Basic 4,152 4,152 4,152 4,152
Weighted average
common shares
outstanding-
Fully diluted 4,152 4,841 4,152 4,152
Net income (loss) per share is based on the weighted average number of common shares and common share equivalents outstanding during each period. Certain common stock equivalents are excluded when their effect would be anti- dilutive.
SOURCE Human Pheromone Sciences, Inc.
Source: PR Newswire (November 13, 2007 - 12:01 PM EST)
News by QuoteMedia
www.quotemedia.com
Billybob_TX
18 years ago
November 14, 2006 - 3:21 PM EST
Human Pheromone Sciences Announces Third Quarter Results
Threefold Growth in Net Revenues Results in Operating and Net Income
SAN JOSE, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ('HPS' or 'the Company') today announced results for the third quarter ended September 30, 2006. Net revenues of $365,000, more than tripled the net revenues of $91,000 in the prior year period, and resulted in net income of $49,000 ($.01 per share) as compared with a net loss of $198,000 ($.05 per share) for the same period of 2005. For the nine months ended September 30, 2006, net revenues were $815,000, a 134% increase from the $348,000 reported in the prior year period, and resulted in a net loss of $177,000 ($.04 per share) as compared with a net loss of $727,000 ($.18 per share) for the same period of 2005. At September 30, 2006, the Company's cash and accounts receivable aggregated $2,027,000 as compared with $463,000 at December 31, 2005.
The Company indicated that the $274,000 growth in revenue in the quarter was primarily attributable to a significant increase in pheromone purchases by the Company's largest customers in this area and $57,000 in revenue attributable to a Licensing Agreement signed by the Company in August of 2006. The balance of cash received by the Company under the License Agreement, $1,693,000 is reflected in the financial statements as deferred income, to be amortized over future quarters. 'The increase in net revenues shows continued consumer acceptance of the efficacy of our currently patented human pheromone technology in the fragrance market, and new interest in its potential in additional consumer markets worldwide. In addition, we are pleased by the progress being made and third party interest in new technology being developed and tested by the Company,' a spokesperson indicated.
Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at www.erox.com.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Renee
2 years ago
Hot Features
Premium
